$DCTH
Delcath Systems Inc

2021 Q3 Form 10-Q Financial Statement

#000156459021055636 Filed on November 09, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q4 2020 Q3
Revenue $522.0K $510.0K $470.0K
YoY Change 11.06% -1.92% 23.68%
Cost Of Revenue $227.0K $210.0K $190.0K
YoY Change 19.47% -25.0% 11.76%
Gross Profit $295.0K $300.0K $280.0K
YoY Change 5.36% 25.0% 34.62%
Gross Profit Margin 56.51% 58.82% 59.57%
Selling, General & Admin $4.036M $4.540M $2.000M
YoY Change 101.8% 118.27% -50.02%
% of Gross Profit 1368.14% 1513.33% 714.29%
Research & Development $2.955M $2.740M $3.260M
YoY Change -9.36% 1.48% 83.15%
% of Gross Profit 1001.69% 913.33% 1164.29%
Depreciation & Amortization $37.00K $40.00K $40.00K
YoY Change -7.5% 0.0% -60.0%
% of Gross Profit 12.54% 13.33% 14.29%
Operating Expenses $6.991M $7.280M $5.260M
YoY Change 32.91% 52.3% -9.0%
Operating Profit -$6.696M -$6.980M -$4.980M
YoY Change 34.46% 53.74% -10.62%
Interest Expense -$420.0K -$20.00K -$40.00K
YoY Change 950.0% -100.12% -97.95%
% of Operating Profit
Other Income/Expense, Net -$9.000K -$30.00K $33.00K
YoY Change -127.27% 725.0%
Pretax Income -$7.125M -$7.030M -$4.990M
YoY Change 42.79% -156.29% -33.64%
Income Tax
% Of Pretax Income
Net Earnings -$7.125M -$7.030M -$4.991M
YoY Change 42.76% -156.29% -33.63%
Net Earnings / Revenue -1364.94% -1378.43% -1061.91%
Basic Earnings Per Share -$0.94
Diluted Earnings Per Share -$939.0K -$1.423M -$1.163M
COMMON SHARES
Basic Shares Outstanding 7.588M 3.936M
Diluted Shares Outstanding 7.588M

Balance Sheet

Concept 2021 Q3 2020 Q4 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $24.87M $28.58M $10.90M
YoY Change 128.12% 185.8% -28.9%
Cash & Equivalents $24.87M $28.58M $11.08M
Short-Term Investments
Other Short-Term Assets $6.146M $2.850M $2.040M
YoY Change 201.27% 46.91% 96.15%
Inventory $1.238M $855.0K $840.0K
Prepaid Expenses
Receivables $69.00K $57.00K $100.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $32.32M $32.34M $13.88M
YoY Change 132.84% 156.3% -18.97%
LONG-TERM ASSETS
Property, Plant & Equipment $1.380M $1.351M $2.420M
YoY Change -42.98% 83.81% 36.72%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $270.0K
YoY Change
Total Long-Term Assets $2.107M $2.297M $2.690M
YoY Change -21.67% 44.01% 52.41%
TOTAL ASSETS
Total Short-Term Assets $32.32M $32.34M $13.88M
Total Long-Term Assets $2.107M $2.297M $2.690M
Total Assets $34.43M $34.64M $16.57M
YoY Change 107.75% 143.7% -12.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.187M $1.774M $1.500M
YoY Change -20.87% -60.86% -69.21%
Accrued Expenses $3.269M $4.859M $6.640M
YoY Change -50.77% -30.06% 1.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $2.000M $2.000M
YoY Change -100.0%
Total Short-Term Liabilities $5.361M $10.04M $10.64M
YoY Change -49.61% -37.26% -67.23%
LONG-TERM LIABILITIES
Long-Term Debt $15.44M $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $1.902M $2.520M $2.650M
YoY Change -28.23% -18.46%
Total Long-Term Liabilities $17.34M $2.520M $2.650M
YoY Change 554.26% -49.52%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.361M $10.04M $10.64M
Total Long-Term Liabilities $17.34M $2.520M $2.650M
Total Liabilities $22.70M $12.56M $13.29M
YoY Change 70.81% -38.95% -64.77%
SHAREHOLDERS EQUITY
Retained Earnings -$415.6M -$395.3M
YoY Change 6.51%
Common Stock $74.00K $60.00K
YoY Change 5900.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.73M $22.08M $3.276M
YoY Change
Total Liabilities & Shareholders Equity $34.43M $34.64M $16.57M
YoY Change 107.75% 143.7% -12.3%

Cashflow Statement

Concept 2021 Q3 2020 Q4 2020 Q3
OPERATING ACTIVITIES
Net Income -$7.125M -$7.030M -$4.991M
YoY Change 42.76% -156.29% -33.63%
Depreciation, Depletion And Amortization $37.00K $40.00K $40.00K
YoY Change -7.5% 0.0% -60.0%
Cash From Operating Activities -$4.524M -$4.600M -$5.190M
YoY Change -12.83% -14.34% -58.01%
INVESTING ACTIVITIES
Capital Expenditures -$56.00K -$70.00K -$490.0K
YoY Change -88.57% 250.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$56.00K -$70.00K -$490.0K
YoY Change -88.57% 250.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 14.12M 22.45M 660.0K
YoY Change 2039.39% -112350.0% -97.51%
NET CHANGE
Cash From Operating Activities -4.524M -4.600M -5.190M
Cash From Investing Activities -56.00K -70.00K -490.0K
Cash From Financing Activities 14.12M 22.45M 660.0K
Net Change In Cash 9.540M 17.78M -5.020M
YoY Change -290.04% -428.65% -135.6%
FREE CASH FLOW
Cash From Operating Activities -$4.524M -$4.600M -$5.190M
Capital Expenditures -$56.00K -$70.00K -$490.0K
Free Cash Flow -$4.468M -$4.530M -$4.700M
YoY Change -4.94% -15.33% -61.97%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y25D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y2M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y2M12D
dcth Class Of Warrant Or Right Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm
P3Y6M
dcth Class Of Warrant Or Right Exercisable Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm
P3Y6M
dcth Class Of Warrant Or Right Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm
P3Y6M
CY2021Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
10834000
CY2020Q4 us-gaap Loans Payable Current
LoansPayableCurrent
382000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
33000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-9000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
60000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
427301000
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
74000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
417449000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-415629000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-395327000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-20000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-104000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
11726000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
22078000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
34425000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
34635000
us-gaap Gross Profit
GrossProfit
906000
us-gaap Gross Profit
GrossProfit
705000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10159000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8457000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10621000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6571000
us-gaap Operating Expenses
OperatingExpenses
20780000
us-gaap Operating Expenses
OperatingExpenses
15028000
us-gaap Operating Income Loss
OperatingIncomeLoss
-19874000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14323000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2832000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-39000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17166000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.75
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.75
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2217611
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2217611
dcth Warrants Down Round Feature Increase Decrease In Equity Amount
WarrantsDownRoundFeatureIncreaseDecreaseInEquityAmount
55000
us-gaap Net Income Loss
NetIncomeLoss
-17127000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
22078000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2148000
CY2021Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
57000
CY2021Q1 dcth Stock Issued During Period Value Exchange Of Warrants For Common Stock
StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonStock
2376000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6747000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
94000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
20006000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1626000
CY2021Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1000
CY2021Q2 dcth Stock Issued During Period Value Exchange Of Warrants For Common Stock
StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonStock
17000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-6430000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-61000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
15159000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2449000
CY2021Q3 dcth Proceeds From Warrant
ProceedsFromWarrant
1171000
CY2021Q3 dcth Cash Issuance Costs Of Warrant
CashIssuanceCostsOfWarrant
-44000
CY2021Q3 dcth Stock Issued During Period Value Exchange Of Warrants For Common Stock
StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonStock
65000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-7125000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
51000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
11726000
CY2020Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
30000
CY2020Q1 dcth Adjustment To Additional Paid In Capital Registration Of Preferred Stock And Related Warrants
AdjustmentToAdditionalPaidInCapitalRegistrationOfPreferredStockAndRelatedWarrants
106000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
6199000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17828000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
144000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
708000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-144000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-7861000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
65000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-8005000
CY2020Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
606000
CY2020Q2 dcth Issuance Of Common Stock And Warrants In Public Offering
IssuanceOfCommonStockAndWarrantsInPublicOffering
19378000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4275000
CY2020Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
-1000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
7702000
CY2020Q3 dcth Exercise Of Series F Warrants
ExerciseOfSeriesFWarrants
602000
CY2020Q3 dcth Atm Offerings
ATMOfferings
66000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-4991000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-103000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
3276000
us-gaap Net Income Loss
NetIncomeLoss
-20302000
us-gaap Net Income Loss
NetIncomeLoss
-17127000
dcth Stock Option Compensation Income Expense
StockOptionCompensationIncomeExpense
6224000
dcth Stock Option Compensation Income Expense
StockOptionCompensationIncomeExpense
25000
dcth Restricted Stock Compensation Income Expense
RestrictedStockCompensationIncomeExpense
406000
us-gaap Depreciation
Depreciation
115000
us-gaap Depreciation
Depreciation
125000
dcth Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
26000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
127000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2832000
us-gaap Paid In Kind Interest
PaidInKindInterest
119000
us-gaap Paid In Kind Interest
PaidInKindInterest
120000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
12000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
383000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
185000
dcth Increase Decrease In Deferred Offering Costs
IncreaseDecreaseInDeferredOfferingCosts
268000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-588000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3032000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1652000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-312000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-256000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16193000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-708000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
26000
dcth Payments Related To Registration Costs
PaymentsRelatedToRegistrationCosts
106000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
19377000
dcth Insurance Financing Principal Payments
InsuranceFinancingPrincipalPayments
382000
dcth Insurance Financing Principal Payments
InsuranceFinancingPrincipalPayments
440000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
14437000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2458000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
601000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16513000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19472000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
84000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-39000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
260000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
897000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28756000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10183000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
29016000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11080000
us-gaap Interest Paid Net
InterestPaidNet
260000
us-gaap Interest Paid Net
InterestPaidNet
7000
us-gaap Lease Cost
LeaseCost
319000
us-gaap Operating Lease Payments
OperatingLeasePayments
451000
us-gaap Proceeds From Lease Payments
ProceedsFromLeasePayments
132000
dcth Reclassification Of Warrants From Liability To Equity
ReclassificationOfWarrantsFromLiabilityToEquity
6199000
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
9000
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
20000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
192000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
729000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reclassifications<span style="font-weight:normal;font-style:normal;"> </span></p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain prior period balances have been reclassified in order to conform to current period presentation. These reclassifications have no effect on previously reported results of operations or loss per share.</p>
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24865000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28575000
CY2021Q3 dcth Loan Agreement Restricted Cash
LoanAgreementRestrictedCash
4000000
CY2021Q3 dcth Letters Of Credit Restricted Cash
LettersOfCreditRestrictedCash
101000
CY2020Q4 dcth Letters Of Credit Restricted Cash
LettersOfCreditRestrictedCash
131000
CY2021Q3 dcth Security For Credit Cards Restricted Cash
SecurityForCreditCardsRestrictedCash
50000
CY2020Q4 dcth Security For Credit Cards Restricted Cash
SecurityForCreditCardsRestrictedCash
50000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
29016000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28756000
CY2021Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
665000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
435000
CY2021Q3 us-gaap Inventory Net
InventoryNet
1238000
CY2020Q4 us-gaap Inventory Net
InventoryNet
855000
CY2021Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
573000
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
420000
CY2021Q3 dcth Prepaid Clinical Trial Expenses Current
PrepaidClinicalTrialExpensesCurrent
1630000
CY2020Q4 dcth Prepaid Clinical Trial Expenses Current
PrepaidClinicalTrialExpensesCurrent
1497000
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
154000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
845000
CY2021Q3 us-gaap Prepaid Royalties
PrepaidRoyalties
124000
CY2021Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
87000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
328000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1995000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2670000
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6183000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6064000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4803000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4713000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1380000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1351000
CY2021Q3 dcth Property Plant And Equipment Depreciation Expense
PropertyPlantAndEquipmentDepreciationExpense
36200
dcth Property Plant And Equipment Depreciation Expense
PropertyPlantAndEquipmentDepreciationExpense
114600
CY2020Q3 dcth Property Plant And Equipment Depreciation Expense
PropertyPlantAndEquipmentDepreciationExpense
32800
dcth Property Plant And Equipment Depreciation Expense
PropertyPlantAndEquipmentDepreciationExpense
124800
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
892379
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
11707
CY2020Q4 dcth Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
2698000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1108000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1598000
CY2021Q3 dcth Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
1507000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
257000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
225000
CY2021Q3 us-gaap Interest Payable Current
InterestPayableCurrent
353000
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
234000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
44000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
104000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3269000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4859000
CY2021Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P12M
us-gaap Operating Lease Cost
OperatingLeaseCost
451000
us-gaap Sublease Income
SubleaseIncome
132000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
192000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
113000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
452000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
113000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
46000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
46000
CY2021Q3 dcth Lessee Operating Lease Liability Payments Due Year Six
LesseeOperatingLeaseLiabilityPaymentsDueYearSix
27000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
797000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
70000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
727000
CY2021Q3 dcth Notes And Loans Payable Gross
NotesAndLoansPayableGross
5000000
CY2021Q3 dcth Discount On Notes And Loans Payable
DiscountOnNotesAndLoansPayable
-398000
dcth Stock Issued During Period Shares Associated With Warrants
StockIssuedDuringPeriodSharesAssociatedWithWarrants
465173
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2458
CY2021Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2475000
CY2021Q3 dcth Number Of Common Shares Remained Available To Be Issued
NumberOfCommonSharesRemainedAvailableToBeIssued
1275250
CY2021Q3 dcth Notes And Loans Payable Net
NotesAndLoansPayableNet
4602000
CY2020Q4 dcth Notes And Loans Payable Gross
NotesAndLoansPayableGross
2000000
CY2020Q4 dcth Notes And Loans Payable Net
NotesAndLoansPayableNet
2000000
dcth Percentage Of Final Payment Included In Gross Amount
PercentageOfFinalPaymentIncludedInGrossAmount
0.0425
dcth Final Payment
FinalPayment
637500
CY2021Q3 us-gaap Loans Payable
LoansPayable
12638000
CY2021Q3 us-gaap Notes Payable
NotesPayable
5000000
CY2021Q3 us-gaap Notes And Loans Payable
NotesAndLoansPayable
17638000
dcth Avenue Warrant Value
AvenueWarrantValue
1309000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.870
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0077
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
8924
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1078499
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.68
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
621750
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.02
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.67
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1698249
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.71
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
260000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
443729
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.20
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
39000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1698249
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
443729
CY2021Q3 dcth Share Based Compensation Income Expense
ShareBasedCompensationIncomeExpense
2449000
dcth Share Based Compensation Income Expense
ShareBasedCompensationIncomeExpense
6224000
dcth Share Based Compensation Income Expense
ShareBasedCompensationIncomeExpense
431000
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
8653000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M12D
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4236687
CY2020Q4 dcth Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
9.13
dcth Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
127755
dcth Class Of Warrant Or Right Weighted Average Exercise Price Issued
ClassOfWarrantOrRightWeightedAverageExercisePriceIssued
0.01
dcth Class Of Warrant Or Right Exercises In Period
ClassOfWarrantOrRightExercisesInPeriod
469933
dcth Class Of Warrant Or Right Weighted Average Exercise Price Exercises In Period
ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod
5.88
CY2021Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3894509
CY2021Q3 dcth Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
9.27
CY2021Q3 dcth Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
3894509
CY2021Q3 dcth Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
9.27
CY2021Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3894509
CY2021Q3 dcth Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
3894509
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7251510
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6285554
dcth Number Of Shares Pre Funded Penny Warrants Outstanding
NumberOfSharesPreFundedPennyWarrantsOutstanding
283755
CY2021Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
7354428
CY2020Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
3917593
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
6665826
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
2015863
CY2021Q3 dcth Weighted Average Number Of Shares Pre Funded Warrants1
WeightedAverageNumberOfSharesPreFundedWarrants1
233215
CY2020Q3 dcth Weighted Average Number Of Shares Pre Funded Warrants1
WeightedAverageNumberOfSharesPreFundedWarrants1
371000
dcth Weighted Average Number Of Shares Pre Funded Warrants1
WeightedAverageNumberOfSharesPreFundedWarrants1
257715
dcth Weighted Average Number Of Shares Pre Funded Warrants1
WeightedAverageNumberOfSharesPreFundedWarrants1
201748
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7587643
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4288593
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6923541
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2217611
CY2021Q1 dcth Percentage Of Enrolled Patients
PercentageOfEnrolledPatients
0.87

Files In Submission

Name View Source Status
0001564590-21-055636-index-headers.html Edgar Link pending
0001564590-21-055636-index.html Edgar Link pending
0001564590-21-055636.txt Edgar Link pending
0001564590-21-055636-xbrl.zip Edgar Link pending
dcth-10q_20210930.htm Edgar Link pending
dcth-10q_20210930_htm.xml Edgar Link completed
dcth-20210930.xsd Edgar Link pending
dcth-20210930_cal.xml Edgar Link unprocessable
dcth-20210930_def.xml Edgar Link unprocessable
dcth-20210930_lab.xml Edgar Link unprocessable
dcth-20210930_pre.xml Edgar Link unprocessable
dcth-ex311_8.htm Edgar Link pending
dcth-ex312_6.htm Edgar Link pending
dcth-ex321_10.htm Edgar Link pending
dcth-ex322_7.htm Edgar Link pending
dcth-ex51_88.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending